Source: http://www.marketwired.com/
SAN DIEGO, CA--(Marketwired - September 22, 2016) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,446,134 providing non-invasive metered nasal spray delivery of octreotide. Currently, octreotide is administered by injection three times per day or in a long acting injectable form to treat acromegaly, flushing episodes and watery diarrhea caused by cancerous tumors (carcinoid syndrome or VIP adenomas). The long acting injectable forms, which are typically administered by healthcare professionals, are associated with pain and irritation at the injection site. According to a comprehensive discussion of current practices of octreotide administration that appeared in BioCentury, Feb. 18, 2013, pp. A8-A9, the long acting forms of octreotide "are administered with large-bore needles that penetrate up to two inches beneath the skin and remain in place 45-120 seconds to deliver the dose, causing pain and discomfort during and long after the injection."
The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where a non-invasive (i.e., non-injectable) form of the drug is unavailable or where speed of onset is important, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.
Read more: http://www.marketwired.com/press-release/aegis-awarded-patent-for-non-invasive-nasal-octreotide-formulation-2160633.htm
